RARE ULTRAGENYX PHARMACEUTICAL INC Investments/Divestments 8-K Filing 2023 - Pipeline Updates Ultragenyx Pharmaceutical Inc. provided updates on its development pipeline, including positive interim data from the Phase 2 portion of the Phase 2/3 Orbit study of UX143, as well as updates on other gene therapy candidates.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC